Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dapsone

FDA-approved product (gel, topical), marketed as Aczone, Dapsone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dapsone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Dermatitis herpetiformis
  • Leprosy

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other anti-acne preparations for topical use; Drugs for treatment of lepra
FDA pharmacologic class
Sulfone FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04BA02

Repurposing investigation

Dapsone is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA11.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae6.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis76.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dapsone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dapsone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris

    NCT00835198 · start 2008-12

    Registered record
    Registry ID
    NCT00835198
    Conditions
    Acne Vulgaris
    Interventions
    Dapsone; Tretinoin; Tretinoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-12
    Completion
    2009-08
    Enrolment
    163

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionDapsone; Tretinoin; Tretinoin
    PhasePhase 4
    Registry statusCompleted

  • IPT and Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Malaria.

    NCT00361114 · start 2006-07

    Registered record
    Registry ID
    NCT00361114
    Conditions
    Malaria
    Interventions
    sulphadoxine/pyrimethamine; Chlorproguanil/dapsone; Sulfadoxine/pyrimethamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2006-07
    Completion
    2007-10
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Interventionsulphadoxine/pyrimethamine; Chlorproguanil/dapsone; Sulfadoxine/pyrimethamine
    PhasePhase 3
    Registry statusTerminated

  • A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash

    NCT00343187 · start 2006-06

    Registered record
    Registry ID
    NCT00343187
    Conditions
    Rash; Non-small-Cell Lung Cancer
    Interventions
    ACZONE (dapsone) Gel, 5%; Vehicle Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-06
    Completion
    2007-07
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRash; Non-small-Cell Lung Cancer
    InterventionACZONE (dapsone) Gel, 5%; Vehicle Control
    PhasePhase 2
    Registry statusTerminated

  • Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria

    NCT00344006 · start 2006-06

    Registered record
    Registry ID
    NCT00344006
    Conditions
    Malaria, Falciparum
    Interventions
    chlorproguanil-dapsone-artesunate; artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-06
    Completion
    2007-08
    Enrolment
    1,395

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum
    Interventionchlorproguanil-dapsone-artesunate; artemether-lumefantrine
    PhasePhase 3
    Registry statusCompleted

  • Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria

    NCT00371735 · start 2006-04

    Registered record
    Registry ID
    NCT00371735
    Conditions
    Malaria, Falciparum
    Interventions
    chlorproguanil-dapsone-artesunate; chlorproguanil-dapsone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-05
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum
    Interventionchlorproguanil-dapsone-artesunate; chlorproguanil-dapsone
    PhasePhase 3
    Registry statusCompleted

  • Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency

    NCT00243542 · start 2005-11

    Registered record
    Registry ID
    NCT00243542
    Conditions
    Acne Vulgaris
    Interventions
    ACZONE Gel, 5%; Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-11
    Completion
    2006-10
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionACZONE Gel, 5%; Vehicle
    PhasePhase 4
    Registry statusCompleted

  • A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

    NCT00249782 · start 2005-11

    Registered record
    Registry ID
    NCT00249782
    Conditions
    Rosacea
    Interventions
    Vehicle control, 2x/day; ACZONE (dapsone) Gel, 5%, 2x/day; ACZONE (dapsone) Gel, 5%, 1x/day; MetroGel® (metronidazole gel), 1.0% 1x/day; ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-11
    Completion
    2006-05
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRosacea
    InterventionVehicle control, 2x/day; ACZONE (dapsone) Gel, 5%, 2x/day; ACZONE (dapsone) Gel, 5%, 1x/day; MetroGel® (metronidazole gel), 1.0% 1x/day +1 more
    PhasePhase 2
    Registry statusCompleted

  • Chlorproguanil-Dapsone in Pregnant Women

    NCT00126971 · start 2005-07

    Registered record
    Registry ID
    NCT00126971
    Conditions
    Malaria
    Interventions
    chlorproguanil-dapsone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2005-07
    Completion
    Not recorded
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Interventionchlorproguanil-dapsone
    PhasePhase 1
    Registry statusTerminated

  • Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi

    NCT00164359 · start 2005-04

    Registered record
    Registry ID
    NCT00164359
    Conditions
    Malaria, Falciparum
    Interventions
    Amodiaquine plus artesunate; chlorproguanil-dapsone plus artesunate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-04
    Completion
    2005-09
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum
    InterventionAmodiaquine plus artesunate; chlorproguanil-dapsone plus artesunate
    PhasePhase 4
    Registry statusCompleted

  • Tolerability and Efficacy of CD+A Compared to AQ+SP for the Treatment of P.Falciparum Malaria in Rwandan Children

    NCT00461578 · start 2005-04

    Registered record
    Registry ID
    NCT00461578
    Conditions
    Malaria
    Interventions
    Chlorproguanil-dapsone + artesunate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-04
    Completion
    2006-10
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionChlorproguanil-dapsone + artesunate
    PhaseNot applicable
    Registry statusCompleted

  • A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%

    NCT00151541 · start 2005-02

    Registered record
    Registry ID
    NCT00151541
    Conditions
    Acne Vulgaris
    Interventions
    Dapsone Topical Gel + adapalene gel 0.1%; Dapsone Topical Gel + benzoyl peroxide gel 4%; Dapsone Topical Gel + vehicle control
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-02
    Completion
    2005-07
    Enrolment
    301

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionDapsone Topical Gel + adapalene gel 0.1%; Dapsone Topical Gel + benzoyl peroxide gel 4%; Dapsone Topical Gel + vehicle control
    PhasePhase 3
    Registry statusCompleted

  • Lapdap and Coartemether for Uncomplicated Malaria

    NCT00118794 · start 2004-09

    Registered record
    Registry ID
    NCT00118794
    Conditions
    Malaria
    Interventions
    Chlorproguanil-dapsone (Lapdap); Lumefantrine-artemether (Coartemether )
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-09
    Completion
    2005-06
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionChlorproguanil-dapsone (Lapdap); Lumefantrine-artemether (Coartemether )
    PhasePhase 3
    Registry statusCompleted

  • Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

    NCT00141037 · start 2004-03

    Registered record
    Registry ID
    NCT00141037
    Conditions
    Kidney Diseases; Kidney Transplantation; Kidney Transplant; Renal Transplantation; Renal Transplant
    Interventions
    Daclizumab; Mycophenolate mofetil (MMF); Prednisone; Tacrolimus; Ganciclovir; Valganciclovir; Trimethoprim and sulfamethoxazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2004-03
    Completion
    2010-11
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Diseases; Kidney Transplantation; Kidney Transplant; Renal Transplantation +1 more
    InterventionDaclizumab; Mycophenolate mofetil (MMF); Prednisone; Tacrolimus +3 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria

    NCT00158561 · start 2004-02

    Registered record
    Registry ID
    NCT00158561
    Conditions
    Malaria; Vivax Malaria
    Interventions
    sulfadoxine-pyrimethamine and chlorproguanil-dapsone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-02
    Completion
    2006-03
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Vivax Malaria
    Interventionsulfadoxine-pyrimethamine and chlorproguanil-dapsone
    PhasePhase 3
    Registry statusCompleted

  • A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania

    NCT00146731 · start 2004-01

    Registered record
    Registry ID
    NCT00146731
    Conditions
    Malaria
    Interventions
    SP; SP + amodiaquine; AQ + artesunate; chlorproguanil-dapsone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-01
    Completion
    2007-09
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionSP; SP + amodiaquine; AQ + artesunate; chlorproguanil-dapsone
    PhasePhase 3
    Registry statusCompleted